AbbVie's Skyrizi Gains Pediatric Indication, Stock Up 7.9%
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
abbvieskyrizi
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
AbbVie’s immunology portfolio secured a key expansion as the FDA approved the blockbuster drug Skyrizi for treatment of pediatric psoriatic disease. The announcement helped propel AbbVie shares to a session high of $253.35, a gain of 7.86% on the day. This regulatory win extends Skyrizi’s market reach to a younger patient population, providing a long-term revenue anchor as the company phases out older patents. The approval was reported by Seeking Alpha on June 26, 2026.
AbbVie is navigating a critical transition period. The company faces an imminent patent cliff for its former top-selling drug Humira, which began facing biosimilar competition in the United States in 2023. Skyrizi, alongside Rinvoq, forms the cornerstone of AbbVie’s post-Humira growth strategy. The pediatric approval arrives amidst a competitive race in the immunology sector, where rivals like Johnson & Johnson and Amgen are also advancing new and existing biologics into younger patient cohorts.
The current market backdrop shows strong investor appetite for growth stories in large-cap pharma. The S&P 500 Health Care sector is up 5.4% year-to-date, slightly lagging the broader index. The catalyst for Skyrizi’s expansion was the successful completion of a Phase 3 pediatric trial, data from which formed the basis of the FDA’s supplemental Biologics License Application review. This label expansion moves earlier than some analyst forecasts, providing a positive surprise.
Previous pediatric expansions for major drugs have shown durable revenue impact. When AbbVie secured pediatric approval for Humira in juvenile idiopathic arthritis in 2008, it solidified the drug’s dominance for over a decade. Similarly, Eli Lilly’s expansion of Taltz into pediatric psoriasis in 2023 contributed to its double-digit annual growth. The timing is strategic, allowing AbbVie to establish Skyrizi as a standard-of-care option before patients transition from pediatric to adult care systems.
AbbVie stock closed at $253.35, up sharply from the day's low of $244.66. The 7.86% single-day gain is significant for a large-cap pharmaceutical stock, which typically exhibits lower volatility. The move added approximately $45 billion to AbbVie’s market capitalization, bringing it near $445 billion based on the latest share count. This performance dramatically outpaces the iShares Biotechnology ETF (IBB), which was flat on the session, and the SPDR S&P Pharmaceuticals ETF (XPH), which gained 0.8%.
Skyrizi's global sales reached $10.2 billion in 2025, making it one of the fastest-growing biologics to cross the $10 billion annual threshold. The pediatric psoriatic disease market is estimated to include over 30,000 addressable patients in the United States alone. Analysts project the new indication could add $1.2 to $1.8 billion in peak annual sales, contributing to a projected overall sales figure for Skyrizi of $17 billion by 2030.
| Metric | Before Announcement (June 25 Close) | After Announcement (June 26 Session High) |
|---|---|---|
| AbbVie Share Price (ABBV) | $234.89 | $253.35 |
| YTD Performance | +12.4% | +21.3% |
| 52-Week Range | $130.22 - $253.35 | $130.22 - $253.35 |
The approval solidifies Skyrizi’s lead in the interleukin-23 inhibitor class. Its main competitor, Johnson & Johnson’s Tremfya, reported 2025 sales of $6.1 billion and does not yet hold a pediatric psoriatic disease indication.
The immediate beneficiary is AbbVie, as the approval de-risks medium-term revenue forecasts and demonstrates commercial execution. Secondary beneficiaries include companies in the drug delivery and patient support service ecosystems, such as Cardinal Health and McKesson, which handle distribution for specialty pharmacies. Contract research organizations that manage pediatric trials, like IQVIA and Syneos Health, may see increased demand for similar studies from other immunology-focused firms.
The primary risk for AbbVie is payer reimbursement dynamics. Pediatric indications often face stringent prior authorization processes from insurers and Medicaid, which could slow the initial uptake of Skyrizi in this new population. A counter-argument is that the long-term benefit of capturing patients early in their disease journey outweighs near-term reimbursement hurdles, as brand loyalty can persist for decades.
Positioning data from options markets showed elevated call buying in ABBV throughout the week leading to the announcement, suggesting some investors anticipated positive news. Institutional flow has been net positive into the healthcare sector for three consecutive weeks, with a notable preference for large-cap names with visible growth pipelines over speculative biotech. This approval is likely to reinforce that trend, pulling capital into established players with regulatory catalysts.
Investors will monitor AbbVie’s second-quarter earnings report on July 29, 2026, for initial commentary on the commercial launch strategy for pediatric Skyrizi and any updated full-year guidance. The next major regulatory catalyst for the immunology portfolio is the FDA decision on Rinvoq for axial spondyloarthritis, with a PDUFA date set for October 2026.
Key technical levels to watch for ABBV include the new resistance at the all-time high of $253.35. A sustained break above this level could target the $270 zone. Support now consolidates around the $245 area, which was the previous session high. Sector watchers should observe the relative performance of the SPDR S&P Biotech ETF (XBI) versus the Health Care Select Sector SPDR Fund (XLV); a widening gap would signal a rotation from growth biotech into profitable large caps.
Yes, the FDA approved Skyrizi for the treatment of pediatric psoriatic disease on June 26, 2026. This covers patients aged 6 to 17 years. The approval is for both psoriatic arthritis and plaque psoriasis manifestations of the disease. It follows a successful Phase 3 clinical trial that demonstrated significant efficacy and a safety profile consistent with the drug's use in adults.
The approval extends AbbVie's lead over Johnson & Johnson in the IL-23 inhibitor segment. Skyrizi is now approved for a broader range of conditions and age groups than J&J's Tremfya. This gives AbbVie's sales force a key competitive advantage in discussions with pediatric rheumatologists and dermatologists. It may pressure J&J to accelerate its own pediatric development programs for Tremfya to avoid ceding this niche market entirely.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.